Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study - PubMed (original) (raw)
Multicenter Study
. 2006 May 1;107(9):3463-8.
doi: 10.1182/blood-2005-09-3640. Epub 2005 Dec 29.
Alessandro Beghini, Giovanni Grillo, Gianpaolo Nadali, Francesca Elice, Carla Barbara Ripamonti, Patrizia Colapietro, Michele Nichelatti, Laura Pezzetti, Monia Lunghi, Antonio Cuneo, Assunta Viola, Felicetto Ferrara, Mario Lazzarino, Francesco Rodeghiero, Giovanni Pizzolo, Lidia Larizza, Enrica Morra
Affiliations
- PMID: 16384925
- DOI: 10.1182/blood-2005-09-3640
Free article
Multicenter Study
Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study
Roberto Cairoli et al. Blood. 2006.
Free article
Abstract
Distinct forms of tyrosine kinase domain (TKD), juxtamembrane domain, exon 8, and internal tandem duplication (ITD) mutations of c-KIT, were observed in about 46% of core binding factor leukemia (CBFL) patients. To evaluate their prognostic significance, 67 adult patients with CBFL were analyzed to ascertain the c-KIT mutation status. In acute myeloid leukemia (AML) with t(8;21), the presence of c-KIT TKD mutation at codon 816 (TKD(816)) was associated with a high white blood cell count at diagnosis (median, 29.60 x 10(9)/L) and a higher incidence (33%) of extramedullary leukemia (EML) during the course of the disease. Data also showed that the TKD(816) mutated patients (n = 12) had a significantly higher incidence of relapse and a lower overall survival (OS) at 24 months, compared with the 17 c-KIT unmutated (c-KIT(-)) patients (90% vs 35.3%, P = .002; 25% vs 76.5%, P = .006, respectively). No difference in relapse incidence (P = .126) and OS (P = .474) was observed between the c-KIT mutated other than TKD(816) (n = 7) and the c-KIT(-) patients. These findings indicate that c-KIT TKD(816) mutation has a negative impact on the outcome of AML with t(8;21).
Similar articles
- The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C, Hills RK, Lamb K, Evans C, Tinsley S, Sellar R, O'Brien M, Yin JL, Burnett AK, Linch DC, Gale RE. Allen C, et al. Leukemia. 2013 Sep;27(9):1891-901. doi: 10.1038/leu.2013.186. Epub 2013 Jun 20. Leukemia. 2013. PMID: 23783394 - Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ, Zhu HH, Jiang Q, Jiang H, Zhang LP, Xu LP, Wang Y, Liu YR, Lai YY, Shi HX, Jiang B, Huang XJ. Qin YZ, et al. Leuk Res. 2014 Dec;38(12):1435-40. doi: 10.1016/j.leukres.2014.09.017. Epub 2014 Oct 6. Leuk Res. 2014. PMID: 25449688 Clinical Trial. - [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M, Li WY, Sun AN, Chen SN, Liang JY, Ding ZX, Feng YF, Wu DP. Qiao M, et al. Zhonghua Xue Ye Xue Za Zhi. 2011 Oct;32(10):679-83. Zhonghua Xue Ye Xue Za Zhi. 2011. PMID: 22339826 Chinese. - The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Larizza L, Magnani I, Beghini A. Larizza L, et al. Leuk Lymphoma. 2005 Feb;46(2):247-55. doi: 10.1080/10428190400007565. Leuk Lymphoma. 2005. PMID: 15621809 Review. - Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Ayatollahi H, Shajiei A, Sadeghian MH, Sheikhi M, Yazdandoust E, Ghazanfarpour M, Shams SF, Shakeri S. Ayatollahi H, et al. Hematol Oncol Stem Cell Ther. 2017 Mar;10(1):1-7. doi: 10.1016/j.hemonc.2016.08.005. Epub 2016 Sep 3. Hematol Oncol Stem Cell Ther. 2017. PMID: 27613372 Review.
Cited by
- Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia.
Shukla M, Abdul-Hay M, Choi JH. Shukla M, et al. Biomedicines. 2024 Aug 6;12(8):1768. doi: 10.3390/biomedicines12081768. Biomedicines. 2024. PMID: 39200232 Free PMC article. Review. - High temporal resolution prediction of mortality risk for single AML patient via deep learning.
Lei Y, Wei H, Gao X. Lei Y, et al. iScience. 2024 Jul 5;27(8):110458. doi: 10.1016/j.isci.2024.110458. eCollection 2024 Aug 16. iScience. 2024. PMID: 39108717 Free PMC article. - Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents.
Jin D, He J, Chen H, Wu W, Han X, Le J, Shu W, Yang Q, Pei S, Cai Z, He D. Jin D, et al. Cancer Med. 2024 Jul;13(14):e7378. doi: 10.1002/cam4.7378. Cancer Med. 2024. PMID: 39031026 Free PMC article. - Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia.
Zhang Z, Huang J, Zhang Z, Shen H, Tang X, Wu D, Bao X, Xu G, Chen S. Zhang Z, et al. Biomark Res. 2024 Jun 10;12(1):60. doi: 10.1186/s40364-024-00600-1. Biomark Res. 2024. PMID: 38858750 Free PMC article. Review. - Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis.
Sheikhi M, Rostami M, Ferns G, Ayatollahi H, Siyadat P, Ayatollahi Y, Khoshnegah Z. Sheikhi M, et al. Caspian J Intern Med. 2024 Spring;15(2):202-214. doi: 10.22088/cjim.15.2.202. Caspian J Intern Med. 2024. PMID: 38807730 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical